ES2186411T3 - Antagonista de receptor de quimioquinas y ciclosporina en terapia combinada. - Google Patents

Antagonista de receptor de quimioquinas y ciclosporina en terapia combinada.

Info

Publication number
ES2186411T3
ES2186411T3 ES99948760T ES99948760T ES2186411T3 ES 2186411 T3 ES2186411 T3 ES 2186411T3 ES 99948760 T ES99948760 T ES 99948760T ES 99948760 T ES99948760 T ES 99948760T ES 2186411 T3 ES2186411 T3 ES 2186411T3
Authority
ES
Spain
Prior art keywords
cyclosporine
chemiokin
antigonist
receptor
combined therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99948760T
Other languages
English (en)
Spanish (es)
Inventor
Hermann-Joseph Grone
Peter J Nelson
Amanda Proudfoot
Timothy N C Wells
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Application granted granted Critical
Publication of ES2186411T3 publication Critical patent/ES2186411T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES99948760T 1998-09-18 1999-09-16 Antagonista de receptor de quimioquinas y ciclosporina en terapia combinada. Expired - Lifetime ES2186411T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98117697A EP1000626A1 (en) 1998-09-18 1998-09-18 Chemokine receptor antagonist and cyclosporin in combined therapy

Publications (1)

Publication Number Publication Date
ES2186411T3 true ES2186411T3 (es) 2003-05-01

Family

ID=8232654

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99948760T Expired - Lifetime ES2186411T3 (es) 1998-09-18 1999-09-16 Antagonista de receptor de quimioquinas y ciclosporina en terapia combinada.

Country Status (23)

Country Link
US (1) US6902728B1 (enExample)
EP (2) EP1000626A1 (enExample)
JP (1) JP2003519082A (enExample)
KR (1) KR100613950B1 (enExample)
CN (1) CN1177613C (enExample)
AR (1) AR021810A1 (enExample)
AT (1) ATE227582T1 (enExample)
AU (1) AU766595B2 (enExample)
BR (1) BR9913846A (enExample)
CA (1) CA2344370A1 (enExample)
DE (1) DE69903964T2 (enExample)
DK (1) DK1113811T3 (enExample)
EA (1) EA003181B1 (enExample)
EE (1) EE04705B1 (enExample)
ES (1) ES2186411T3 (enExample)
HK (1) HK1041225B (enExample)
IL (2) IL141899A0 (enExample)
NO (1) NO20011371L (enExample)
PT (1) PT1113811E (enExample)
SI (1) SI1113811T1 (enExample)
UA (1) UA60379C2 (enExample)
WO (1) WO2000016796A1 (enExample)
ZA (1) ZA200101909B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
US6740636B2 (en) * 2000-07-31 2004-05-25 Schering Aktiengesellschaft Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection
LT5132B (lt) 2000-07-31 2004-05-25 Schering Aktiengesellschaft Nepeptidiniai ccr1 receptorių antagonistai derinyje su ciklosporinu a širdies transplanto atmetimui gydyti
EP2185719B1 (en) 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
WO2017040515A1 (en) * 2015-08-31 2017-03-09 Hitachi Chemical Co., Ltd. Molecular methods for assessing post kidney transplant complications
JP6624704B2 (ja) 2015-08-31 2019-12-25 日立化成株式会社 尿路上皮疾患の評価のための分子法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221089B1 (en) * 1994-12-08 2002-08-28 Glaxo Group Ltd Rantes peptide derivates with antagonistic effect and uses thereof
EP0845994A1 (en) * 1995-08-09 1998-06-10 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
US6184235B1 (en) * 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
WO1998006751A1 (en) * 1996-08-16 1998-02-19 Research Corporation Technologies, Inc. Mcp-3, rantes and mip-1alpha receptor antagonists

Also Published As

Publication number Publication date
PT1113811E (pt) 2003-03-31
NO20011371D0 (no) 2001-03-16
US6902728B1 (en) 2005-06-07
CA2344370A1 (en) 2000-03-30
EE04705B1 (et) 2006-10-16
AU6191499A (en) 2000-04-10
EA200100366A1 (ru) 2001-08-27
BR9913846A (pt) 2001-06-05
EP1000626A1 (en) 2000-05-17
DE69903964D1 (en) 2002-12-19
SI1113811T1 (en) 2003-04-30
KR100613950B1 (ko) 2006-08-18
EA003181B1 (ru) 2003-02-27
CN1177613C (zh) 2004-12-01
KR20010075060A (ko) 2001-08-09
JP2003519082A (ja) 2003-06-17
EE200100159A (et) 2002-08-15
DK1113811T3 (da) 2003-03-10
ZA200101909B (en) 2001-09-11
ATE227582T1 (de) 2002-11-15
CN1319021A (zh) 2001-10-24
EP1113811B1 (en) 2002-11-13
IL141899A0 (en) 2002-03-10
HK1041225B (zh) 2005-04-22
IL141899A (en) 2007-12-03
NO20011371L (no) 2001-03-16
AU766595B2 (en) 2003-10-16
AR021810A1 (es) 2002-08-07
UA60379C2 (uk) 2003-10-15
WO2000016796A1 (en) 2000-03-30
DE69903964T2 (de) 2003-03-27
HK1041225A1 (en) 2002-07-05
EP1113811A1 (en) 2001-07-11

Similar Documents

Publication Publication Date Title
LTC1131065I2 (lt) Dialkilfumaratai, skirti autoimuninėms ligoms gydyti
AU5811001A (en) Cxcr4 antagonist treatment of hematopoietic cells
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
AR033342A1 (es) Una composicion otica topica o intranasal para tratar el dolor otico y el uso topico de agonistas de opioides kapa para tratar el dolor otico
DE69721021D1 (de) Blasenmukosa mit zellen für die rekonstruktion von geweben
ATE333896T1 (de) Vaskularisierungsinhibitoren
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
EA200500149A1 (ru) Тканевые протективные цитокины для защиты, восстановления и стимуляции реактивных клеток, тканей и органов
ATE303804T1 (de) Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten
TR200200118T2 (tr) Yeni bileşimler
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
ES2195638T3 (es) Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida.
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
NO2019032I1 (no) Treosulfan
MX2007004025A (es) Uso de derivados del acido nordihidroguaiaretico en el tratamiento de cancer e infecciones microbial y viral resistente a farmacos._.
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
AR021810A1 (es) Antagonista receptor de quiomicina y ciclosporina en terapia combinada
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
ES2153584T3 (es) Piridiniminil-1,2-benzisoxazol y -benzisotiazol como antipsicoticos.
JP2003519082A5 (enExample)